# **Press Releases**

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email link below.

# **Get News Alerts by Email**

All Years		•
Search		
	Go	

**Advanced Search** 

May 09 2024

BioLife Solutions Reports First Quarter 2024 Financial Results

Cell Processing revenue increased 10% sequentially to \$16.2 million GAAP gross margin of 38% and net loss of \$10.2 million Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of

Apr 30 2024

BioLife Solutions to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Apr 18 2024

BioLife Solutions Announces the Divestiture of its Stirling Freezer Business

BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader...

Mar 04 2024

BioLife Solutions to Present at TD Cowen and Key Bank Investor Conferences

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

### Feb 29 2024

## BioLife Solutions Reports Fourth Quarter and Full Year 2023 Financial Results

Fourth quarter Cell Processing revenue up 11% sequentially to \$14.8 million, and positive adjusted EBITDA of \$700,000 Expects 2024 revenue of \$95.5 - \$100.0 million excluding freezer business and...

#### Feb 20 2024

<u>BioLife Solutions to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update on February 29, 2024</u>

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

### lan 08 2024

<u>BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited</u> Revenue

Fourth quarter Cell Processing revenue increased 11% sequentially to \$14.8 million BOTHELL, Wash., Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"),...

#### Nov 09 2023

BioLife Solutions Reports Third Quarter 2023 Financial Results

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene...

#### Nov 02 2023

<u>BioLife Solutions to Provide Third Quarter 2023 Financial Results and Business Update on November 9, 2023</u>


BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

#### Oct 19 2023

<u>BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue</u> with Updated Outlook for 2023

Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience Garrie Richardson appointed Chief Revenue Officer Preliminary Q3 revenue of \$33.3...







https://investors.biolifesolutions.com/press-releases?l=10&o=0